公开(公告)号：US20060182814A1

公开(公告)日：2006-08-17

申请号：US11343977

申请日：2006-01-30

申请人： Leo Martis ,  Lee Henderson

发明人： Leo Martis ,  Lee Henderson

IPC分类号： A61K33/00 ,  A61K31/70

CPC分类号： A61K33/14 ,  A61K33/00 ,  A61K45/06 ,  A61M1/287 ,  A61K33/10 ,  A61K31/7004 ,  A61K31/19 ,  A61K2300/00

摘要： A peritoneal dialysis solution that is biochemically balanced to correct metabolic acidosis associated with chronic renal failure in a more physiological manner. The peritoneal dialysis solution has a physiological pH, e.g. pH of 70 to 74 and contains bicarbonate at a concentration that is found in normal blood. Additionally, the solution contains carbon dioxide at a partial pressure that is similar to partial pressure of carbon dioxide found in normal blood. The peritoneal dialysis solution also contains a weak acid with a pKa of less than 5.0.

摘要翻译： 腹膜透析液，其生物化学平衡，以更生理的方式纠正与慢性肾衰竭相关的代谢性酸中毒。 腹膜透析溶液具有生理pH，例如， pH值为70至74，并含有在正常血液中发现的浓度的碳酸氢盐。 此外，该溶液含有与正常血液中发现的二氧化碳分压相似的分压下的二氧化碳。 腹膜透析液还含有pKa小于5.0的弱酸。

公开(公告)号：US20050020507A1

公开(公告)日：2005-01-27

申请号：US10628065

申请日：2003-07-25

申请人： Paul Zieske ,  Leo Martis ,  Carolyn Choo

发明人： Paul Zieske ,  Leo Martis ,  Carolyn Choo

IPC分类号： A61J1/00 ,  A61J1/20 ,  A61K9/00 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61M1/16 ,  A61M1/28 ,  A61K31/70

CPC分类号： A61J1/2093 ,  A61J1/10 ,  A61J1/2024 ,  A61J1/2027 ,  A61K9/0019 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61M1/1668 ,  A61M1/28 ,  A61M1/287

摘要： Dialysis solutions with enhanced biocompatibility are provided. The dialysis solutions include a first acidic solution and a second acidic solution that are admixed to form a ready-to-use dialysis solution with reduced levels of glucose degradation products prior to use. The first acidic solution includes a dextrose concentrate, and the second acidic solution includes a buffer concentrate, such as a lactate-based buffer. The first and second acid solutions are separately sterilized prior to mixing to form the ready-to-use dialysis solutions. The dialysis solutions can be used in a variety of different applications, such as infusion into a patient during peritoneal dialysis.

摘要翻译： 提供具有增强的生物相容性的透析溶液。 透析溶液包括第一酸性溶液和第二酸性溶液，其混合以形成使用前葡萄糖降解产物水平降低的即用型透析溶液。 第一酸性溶液包括葡萄糖浓缩物，第二酸性溶液包括缓冲浓缩物，例如基于乳酸盐的缓冲液。 将第一和第二酸溶液在混合之前分开灭菌以形成即用型透析溶液。 透析溶液可用于各种不同的应用，例如在腹膜透析期间输注到患者体内。

公开(公告)号：US06475529B2

公开(公告)日：2002-11-05

申请号：US09918328

申请日：2001-07-30

申请人： Annick Duponchelle ,  Dirk Faict ,  Patrick Balteau ,  Jean-Pierre Hartman ,  Leo Martis ,  Francesco Peluso

发明人： Annick Duponchelle ,  Dirk Faict ,  Patrick Balteau ,  Jean-Pierre Hartman ,  Leo Martis ,  Francesco Peluso

IPC分类号： A61K3300

CPC分类号： A61M1/287 ,  A61K33/14 ,  A61M1/1654 ,  A61K33/10 ,  A61K2300/00

摘要： The present invention provides devices and methods for stabilizing bicarbonate-based solutions for peritoneal dialysis or hemofiltration. The bicarbonate-based solutions of the present invention are formulated and stored in at least two parts—an alkaline bicarbonate concentrate and an acidic concentrate. The alkaline bicarbonate concentrate is adjusted to have a pH of about 8.6 to 10.0. The acidic concentrate is adjusted to have a stable, acidic pH ranging from about 1.0 to 3.0. Upon mixing, although some variation in the pH of the mixed bicarbonate solution exists, the inventors have discovered that with the appropriate selection of the parameters of the concentrates, the pH of the mixed solution is always within an acceptable physiological range.

公开(公告)号：US06380163B1

公开(公告)日：2002-04-30

申请号：US07995106

申请日：1992-12-22

申请人： Leo Martis ,  Ron Burke ,  Dirk Faict

发明人： Leo Martis ,  Ron Burke ,  Dirk Faict

IPC分类号： A61K3808

CPC分类号： A61K38/018 ,  A61K38/02 ,  A61M1/287

摘要： The present invention provides an improved dialysis solution. The improved dialysis solution provides for the use of specific polypeptides as an osmotic agent with an additional osmotic agent such as dextrose. To this end, the present invention provides, in an embodiment, a peritoneal dialysis solution comprising as osmotic agents approximately 0.25 to about 4.0% (w/v) polypeptides and approximately 0.5% to about 4.0% (w/v) dextrose. The polypeptides have well defined characteristics.

摘要翻译： 本发明提供了一种改进的透析溶液。 改进的透析溶液提供使用特定多肽作为渗透剂与另外的渗透剂如葡萄糖。 为此，在一个实施方案中，本发明提供包含约0.25至约4.0％（w / v）多肽和约0.5％至约4.0％（w / v）葡萄糖的渗透剂的腹膜透析溶液。 多肽具有明确的特征。

公开(公告)号：US08546097B2

公开(公告)日：2013-10-01

申请号：US12618442

申请日：2009-11-13

申请人： Leo Martis ,  Mehul Patel ,  Joseph A. Giertych ,  James W. Mongoven ,  Jacqueline A. Kunzler ,  William F. Owen, Jr.

发明人： Leo Martis ,  Mehul Patel ,  Joseph A. Giertych ,  James W. Mongoven ,  Jacqueline A. Kunzler ,  William F. Owen, Jr.

IPC分类号： C12G1/00

CPC分类号： A61K31/716 ,  C12Q1/04 ,  G01N2333/4722 ,  Y10S436/815

摘要： Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions are provided. The methods and compositions employ modified bioburden testing and the detection of peptidoglycan. A novel cause of aseptic peritonitis is provided—aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. In this regard, testing for peptidoglycans can be utilized to effectively prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including an icodextrin and the like.

摘要翻译： 提供了用于检测腹膜透析溶液中微生物污染物的方法和组合物。 方法和组合物采用修饰的生物负载测试和肽聚糖的检测。 提供无菌性腹膜炎的新原因 - 与透析溶液的革兰氏阳性微生物污染相关的无菌性腹膜炎。 肽聚糖是革兰氏阳性细菌细胞壁的主要成分，因此可以作为革兰氏阳性菌的标记物。 在这方面，可以利用肽聚糖的测试来有效地预防使用腹膜透析溶液的患者腹膜炎，例如含有包含icodextrin等的葡萄糖聚合物的腹膜透析溶液。

公开(公告)号：US07053059B2

公开(公告)日：2006-05-30

申请号：US10628065

申请日：2003-07-25

申请人： Paul Zieske ,  Leo Martis ,  Carolyn Choo

发明人： Paul Zieske ,  Leo Martis ,  Carolyn Choo

IPC分类号： A61K31/70

CPC分类号： A61J1/2093 ,  A61J1/10 ,  A61J1/2024 ,  A61J1/2027 ,  A61K9/0019 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61M1/1668 ,  A61M1/28 ,  A61M1/287

摘要： Dialysis solutions with enhanced biocompatibility are provided. The dialysis solutions include a first acidic solution and a second acidic solution that are admixed to form a ready-to-use dialysis solution with reduced levels of glucose degradation products prior to use. The first acidic solution includes a dextrose concentrate, and the second acidic solution includes a buffer concentrate, such as a lactate-based buffer. The first and second acid solutions are separately sterilized prior to mixing to form the ready-to-use dialysis solutions. The dialysis solutions can be used in a variety of different applications, such as infusion into a patient during peritoneal dialysis.

摘要翻译： 提供具有增强的生物相容性的透析溶液。 透析溶液包括第一酸性溶液和第二酸性溶液，其混合以形成使用前葡萄糖降解产物水平降低的即用型透析溶液。 第一酸性溶液包括葡萄糖浓缩物，第二酸性溶液包括缓冲浓缩物，例如基于乳酸盐的缓冲液。 将第一和第二酸溶液在混合之前分开灭菌以形成即用型透析溶液。 透析溶液可用于各种不同的应用，例如在腹膜透析期间输注到患者体内。

公开(公告)号：US20050191717A1

公开(公告)日：2005-09-01

申请号：US10789320

申请日：2004-02-27

申请人： Leo Martis ,  Mehul Patel ,  Joseph Giertych ,  James Mongoven ,  Jacqueline Kunzler ,  William Owen

发明人： Leo Martis ,  Mehul Patel ,  Joseph Giertych ,  James Mongoven ,  Jacqueline Kunzler ,  William Owen

IPC分类号： C12Q1/04 ,  C12Q1/26 ,  C12Q1/37 ,  C12Q1/54 ,  A61K31/715

CPC分类号： A61K31/716 ,  C12Q1/04 ,  G01N2333/4722 ,  Y10S436/815

摘要： Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions are provided. The methods and compositions employ modified bioburden testing and the detection of peptidoglycan. A novel cause of aseptic peritonitis is provided—aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. In this regard, testing for peptidoglycans can be utilized to effectively prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including an icodextrin and the like.

摘要翻译： 提供了用于检测腹膜透析溶液中微生物污染物的方法和组合物。 方法和组合物采用修饰的生物负载测试和肽聚糖的检测。 提供无菌性腹膜炎的新原因 - 与透析溶液的革兰氏阳性微生物污染相关的无菌性腹膜炎。 肽聚糖是革兰氏阳性细菌细胞壁的主要成分，因此可以作为革兰氏阳性菌的标记。 在这方面，可以利用肽聚糖的测试来有效地预防使用腹膜透析溶液的患者腹膜炎，例如含有包含icodextrin等的葡萄糖聚合物的腹膜透析溶液。

公开(公告)号：US20060263842A1

公开(公告)日：2006-11-23

申请号：US11457330

申请日：2006-07-13

申请人： Leo Martis ,  Mehul Patel ,  Joseph Giertych ,  James Mongoven ,  Jacqueline Kunzler ,  William Owen

发明人： Leo Martis ,  Mehul Patel ,  Joseph Giertych ,  James Mongoven ,  Jacqueline Kunzler ,  William Owen

IPC分类号： C12Q1/37

CPC分类号： A61K31/716 ,  C12Q1/04 ,  G01N2333/4722 ,  Y10S436/815

摘要： Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions are provided. The methods and compositions employ modified bioburden testing and the detection of peptidoglycan. A novel cause of aseptic peritonitis is provided—aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. In this regard, testing for peptidoglycans can be utilized to effectively prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including an icodextrin and the like.

摘要翻译： 提供了用于检测腹膜透析溶液中微生物污染物的方法和组合物。 方法和组合物采用修饰的生物负载测试和肽聚糖的检测。 提供无菌性腹膜炎的新原因 - 与透析溶液的革兰氏阳性微生物污染相关的无菌性腹膜炎。 肽聚糖是革兰氏阳性细菌细胞壁的主要成分，因此可以作为革兰氏阳性菌的标记物。 在这方面，可以利用肽聚糖的测试来有效地预防使用腹膜透析溶液的患者腹膜炎，例如含有包含icodextrin等的葡萄糖聚合物的腹膜透析溶液。

公开(公告)号：US5698230A

公开(公告)日：1997-12-16

申请号：US822519

申请日：1997-03-24

申请人： Leo Martis ,  Michael R. Jones

发明人： Leo Martis ,  Michael R. Jones

IPC分类号： A61K31/195 ,  A61K31/198 ,  A61K31/40 ,  A61K31/405 ,  A61K31/415 ,  A61K33/10 ,  A61K33/14 ,  A61M1/28 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61K31/19 ,  A61K31/70

CPC分类号： A61K31/415 ,  A61K31/195 ,  A61K31/40 ,  A61K31/405 ,  A61K33/10 ,  A61K33/14 ,  A61M1/287

摘要： The present invention provides a dialysis solution that contains amino acids for treating and/or preventing malnutrition in a peritoneal dialysis patient. The amino acid composition is optimized to minimize metabolic acidosis while normalizing amino acid plasma profiles.

公开(公告)号：US5631025A

公开(公告)日：1997-05-20

申请号：US423174

申请日：1995-04-18

申请人： Ty R. Shockley ,  Leo Martis ,  Lee W. Henderson ,  John Moran ,  Masaaki Nakayama

发明人： Ty R. Shockley ,  Leo Martis ,  Lee W. Henderson ,  John Moran ,  Masaaki Nakayama

IPC分类号： A61K33/14 ,  A61K38/00 ,  A61K31/70 ,  A61K33/10

CPC分类号： A61K33/14

摘要： An improved peritoneal dialysis solution and methods of administering same to a patient are provided. Pursuant to the present invention, the sodium concentration in the solution is decreased thus causing sodium to be transported from the circulation to the peritoneal cavity. This provides for an improved ultrafiltration profile for the same initial osmolality when compared to standard solutions. Also, the same ultrafiltration profile as standard solutions can be achieved with lower initial osmolalities.

摘要翻译： 提供改进的腹膜透析溶液及其给予患者的方法。 根据本发明，溶液中的钠浓度降低，从而使钠从循环输送到腹膜腔。 与标准溶液相比，这提供了与初始渗透压相同的改进的超滤分布。 此外，与标准溶液相同的超滤曲线可以用较低的初始渗透压实现。